Esophageal Cancer Pathogenesis and Therapeutic Strategies

Esophageal cancer encompasses two principal histological subtypes—adenocarcinoma and squamous cell carcinoma—each exhibiting distinct aetiologies and molecular landscapes. Adenocarcinoma often arises in the distal oesophagus against a background of chronic gastro-oesophageal reflux and Barrett’s metaplasia, characterised by genomic instability, TP53 mutation, HER2 amplification and activation of proliferation pathways. Squamous cell carcinoma predominates in regions with tobacco, alcohol and nutritional risk factors, and is driven by squamous-specific alterations including SOX2 overexpression and dysregulated keratinocyte differentiation. Both subtypes engage a complex tumour microenvironment (TME) in which cancer-associated fibroblasts, infiltrating immune cells, endothelial networks and extracellular matrix jointly shape progression, immune evasion and therapeutic resistance. Key processes such as epithelial–mesenchymal transition, immune checkpoint upregulation and metabolic reprogramming facilitate invasion and metastasis. Current therapeutic strategies integrate surgery, radiotherapy and platinum-based chemoradiation, increasingly refined by molecular profiling to guide targeted agents against EGFR, VEGF or HER2, and by immune checkpoint inhibitors directed at PD-1/PD-L1 or CTLA-4. Neoadjuvant approaches seek to downstage tumours and exploit predictive biomarkers—including circulating DNA, tumour-resident microbiota and immune signatures—to personalise treatment intensity. Emerging modalities under clinical evaluation include TAM-derived chemokine blockade, microbiome-based risk models, multi-omic classifiers and early AI-driven prognostic tools. Together, these advances aim to improve survival through precision medicine frameworks that align tumour biology, host immunity and therapeutic innovation.

Research from Nature Portfolio

Recent multi-omic analysis of oesophageal adenocarcinoma has delineated genomic, transcriptomic and methylation signatures that correlate with treatment response and survival. Immune profiling revealed distinct “hot” and “cold” clusters, identifying patients likely to benefit from checkpoint blockade. Integrated single-cell transcriptome studies of squamous cell carcinoma have exposed remarkable heterogeneity among fibroblast and immune compartments, uncovering tumour-specific stromal subsets and diverse antigen-presenting cell states that influence prognosis and therapeutic sensitivity. In a complementary single-cell atlas of mouse oesophageal carcinogenesis, epithelial transition states and early immune shifts from type-1 to type-3 responses were shown to foster a chronic inflammatory milieu, pinpointing transition markers that could enable earlier diagnosis and intervention.

Esophageal Cancer Pathogenesis and Therapeutic Strategies publication trend

The graph below shows the total number of articles in esophageal cancer pathogenesis and therapeutic strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Tumour microenvironment (TME): The complex ecosystem of non-neoplastic cells and extracellular components surrounding tumour cells, influencing growth and drug response.

Epithelial–mesenchymal transition (EMT): A cellular programme whereby epithelial cells acquire mesenchymal traits, enhancing motility and invasiveness.

Neoadjuvant therapy: Treatment administered before the main intervention (usually surgery) to reduce tumour burden and improve outcomes.

Multi-omic analysis: Integrated examination of genomic, transcriptomic, epigenomic and other molecular data layers to define comprehensive tumour profiles.

Immune checkpoint inhibitor: A therapeutic antibody that blocks inhibitory pathways in T cells (such as PD-1/PD-L1) to enhance anti-tumour immunity.

References

1. Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nature Communications (2023).
2. Tumor‐Resident Microbiota‐Based Risk Model Predicts Neoadjuvant Therapy Response of Locally Advanced Esophageal Squamous Cell Carcinoma Patients. Advanced Science (2024).
3. Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research (2023).
4. Analyzing the Impact of Oncological Data at Different Time Points and Tumor Biomarkers on Artificial Intelligence Predictions for Five-Year Survival in Esophageal Cancer. Machine Learning and Knowledge Extraction (2024).
5. Advances in targeted therapy for esophageal cancer. Signal Transduction and Targeted Therapy (2020).
6. Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment. Nature Communications (2021).
7. Single-cell transcriptomic analysis in a mouse model deciphers cell transition states in the multistep development of esophageal cancer. Nature Communications (2020).